Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Repare Therapeutics ( (RPTX) ) is now available.
On October 22, 2025, Repare Therapeutics announced the availability of an abstract related to their Phase 1 LIONS trial of RP-1664. This preliminary data, showcasing the safety and antitumor activity of RP-1664 in advanced solid tumors, will be presented at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
The most recent analyst rating on (RPTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.
Spark’s Take on RPTX Stock
According to Spark, TipRanks’ AI Analyst, RPTX is a Neutral.
Repare Therapeutics’ overall stock score of 60 is driven by moderate technical momentum and a positive corporate event, which offset financial challenges. The licensing deal provides strategic advantages, while technical indicators suggest short-term strength. However, ongoing financial losses and valuation concerns temper the stock’s attractiveness.
To see Spark’s full report on RPTX stock, click here.
More about Repare Therapeutics
Repare Therapeutics Inc. operates in the biotechnology industry, focusing on developing innovative cancer therapies. The company specializes in creating targeted treatments for solid tumors, with a market focus on advanced cancer therapeutics.
Average Trading Volume: 117,618
Technical Sentiment Signal: Sell
Current Market Cap: $80.76M
For an in-depth examination of RPTX stock, go to TipRanks’ Overview page.